StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Research analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Down 2.0 %

CTSO stock opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm’s fifty day simple moving average is $1.07 and its 200-day simple moving average is $1.05. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The company has a market capitalization of $54.68 million, a P/E ratio of -2.78 and a beta of 0.78.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds have recently bought and sold shares of the business. Avenir Corp grew its stake in Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after acquiring an additional 118,387 shares during the period. Raymond James Financial Inc. purchased a new position in Cytosorbents during the fourth quarter valued at $99,000. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at about $30,000. Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Finally, Skylands Capital LLC increased its stake in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.